JEUVEAU
Peakprabotulinum toxin type a
BLAINJECTIONINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
JEUVEAU (prabotulinum toxin type a) is acetylcholine release inhibitors [moa]. First approved in 2019.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEUVEAU is a purified botulinum toxin type A approved for aesthetic use to treat moderate-to-severe dynamic facial wrinkles and frown lines. It works by inhibiting acetylcholine release at the neuromuscular junction, paralyzing targeted facial muscles. The product represents a newer entrant in the competitive botulinum toxin market, approved by the FDA in February 2019.
Peak
Product is at peak commercial maturity in the competitive aesthetic injectable market; team focus is likely on defending market share and managing competitive pressures rather than growth acceleration.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on JEUVEAU offers exposure to the competitive aesthetic injectable market and demand-generation strategies in a mature category. Roles emphasize sales execution, payer negotiations, and practitioner education rather than clinical innovation or novel mechanism development.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.